Clinical Trials Logo

Carcinoma, Non-Small-Cell Lung clinical trials

View clinical trials related to Carcinoma, Non-Small-Cell Lung.

Filter by:

NCT ID: NCT04385368 Completed - Clinical trials for Carcinoma, Non-Small-Cell Lung

Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)

MERMAID-1
Start date: July 17, 2020
Phase: Phase 3
Study type: Interventional

This is a Phase III, randomized, parallel-arm, placebo controlled, double blind, multicenter study assessing the efficacy and safety of durvalumab versus placebo following SoC chemotherapy in patients with completely resected stage II-III NSCLC who are MRD+ post surgery

NCT ID: NCT04351334 Completed - Clinical trials for Non-Small-Cell Lung Carcinoma

Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns

Start date: March 27, 2020
Phase:
Study type: Observational

This study aims to understand patient profiles, treatment patterns, and clinical outcomes among ALK-positive NSCLC patients treated with alectinib, and post-alectinib treatment patterns and outcomes.

NCT ID: NCT04345146 Completed - Clinical trials for Non-small Cell Lung Cancer

Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLC

Start date: January 1, 2020
Phase: Phase 2
Study type: Interventional

This Phase II randomized study is to determine the efficacy and safety of Bevacizumab combined with fractionated stereotactic radiation therapy(FSRT) in patients with 1 to 10 brain metastases in non-small cell lung cancer by assessing the treatment response, perilesional edema, neurological symptoms and quality of life.

NCT ID: NCT04342377 Completed - Lung Cancer Clinical Trials

The Canada Lymph Node Score Project: A Crossover Trial

CLNS
Start date: November 30, 2020
Phase: Phase 3
Study type: Interventional

Before deciding on treatment for patients with lung cancer, a critical step in the investigation is finding out whether the lymph nodes in the chest contain cancer cells. This is accomplished with a biopsy of the lymph nodes through the airway wall, known as Endobronchial Ultrasound-guided Transbronchial Needle Aspiration. Guidelines require that every single lymph node in the chest be biopsied through a process called Systematic Sampling. However, emerging data suggests that the lymph nodes that appear benign on imaging and ultrasound do not need a biopsy. A proposed alternative to the inefficient Systematic Sampling is the simplified Selective Targeted Sampling of the lymph nodes, whereby only lymph nodes that look malignant are biopsied. This trial will evaluate the simplified Selective Targeted Sampling of lymph nodes and compare it to Systematic Sampling to see whether it is equally as effective in staging lung cancer.

NCT ID: NCT04314895 Completed - Lung Cancer Clinical Trials

Trial of NanoPac Intratumoral Injection in Lung Cancer

Start date: April 14, 2021
Phase: Phase 2
Study type: Interventional

This study evaluates the use of NanoPac injected directly into tumors in the lung of people with lung cancer.

NCT ID: NCT04311034 Completed - Clinical trials for Non Small Cell Lung Cancer

A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer

Start date: September 26, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of RC48-ADC for injection in subjects with advanced non-small cell lung cancer with HER2 overexpression or HER2 mutation.

NCT ID: NCT04309422 Completed - Clinical trials for Non Small Cell Lung Cancer

Texture Features and PDL1 in CT-PET 18 FDG

Start date: April 1, 2018
Phase:
Study type: Observational

Search correlation between texture features in CT-PET 18 FDG and overexpression of PDL1 in non-small cell lung carcinomas during the inital staging. The hypothesis is that overexpression of PDL1is correlated with at least one texture feature among those selected. 84 CT-PET 18 FDG at the initial staging of a non small cell lung carcinoma (adenocarcinoma or squamous cell carcinoma), whose the biopsed site was the primitive site or the drainage lymphadenopathy, without previous treatment, were recruited and analyzed by a software allowing to estimate texture features.

NCT ID: NCT04299048 Completed - Colorectal Cancer Clinical Trials

Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.

Start date: November 17, 2020
Phase: Phase 1
Study type: Interventional

Study to assess the safety and tolerability of repeated doses of an investigational new drug in patients with cancer and cachexia.

NCT ID: NCT04294108 Completed - Atrial Fibrillation Clinical Trials

Why in Hospital After VATS Lobectomy

Start date: April 20, 2020
Phase:
Study type: Observational

The study aims to identify specific or potential reasons that prolong the length of hospital stay after video-assisted thoracoscopic surgery lobectomy. The hypothesis is that patients who are still in hospital after video-assisted thoracoscopic surgery lobectomy are associated with prolonged air leak, infection, pneumonia, atrial fibrillation or other complications or social factors.

NCT ID: NCT04271384 Completed - Clinical trials for Non-small Cell Lung Cancer Stage I

Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer

Start date: February 12, 2020
Phase: Phase 2
Study type: Interventional

Stage 1 non-small cell lung cancer (NSCLC) carries up to 30% chance of relapse in 5 years. This a phase 2 study that aims to determine the pathological complete response of the combination of stereotactic ablative radiotherapy (SABR) plus nivolumab as neoadjuvant treatment in early-stage non-small cell lung cancer. The patients will receive standard SABR + nivolumab at a dose of 360 mg every 21 days for 3 doses. The patient will undergo surgery 10 weeks after the last radiotherapy dose.